Methylprednisolone

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Methylprednisolone

Examples of brand names: Urbason [DE]

ATC code: H02AB04

Main use (for orientation): Inflammatory diseases

Documented research summary

A severe neuropsychiatric case after nabiximols in MS with baclofen and methylprednisolone; causal attribution undetermined, not an isolated pair and no pharmacokinetics. Other results mainly comparator arms/acronyms.

Uncertainties and limitations

Solu-Medrol injectable sodium succinate, not depot acetate. Case report does not permit isolation of methylprednisolone–cannabis causality.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD + THC (nabiximols) – clinical signals

Finding ID: B0255

Type of result: Case report, causality uncertain

Observation: Behavioural changes including suicidal thoughts after 4 weeks of nabiximols.

Mechanism: Possible additive/neuropsychiatric effect during multiple-drug treatment

Study type: Single case

Context studied: Woman with MS simultaneously taking baclofen and methylprednisolone.

Clinical interpretation: Safety signal with several possible causes

Limitations and uncertainties: Not an isolated methylprednisolone interaction, no pharmacokinetics; CBD/THC not separated. Full-text access to PMC4407789/DOI failed; limited to abstract.

Original sources for this finding: Sativex-induced neurobehavioral effects: causal or concausal? A practical advice! [CA_P_25881038]

References and access status

[V2_LABEL_D0035] SOLU-MEDROL (METHYLPREDNISOLONE SODIUM SUCCINATE) INJECTION, POWDER, FOR SOLUTION [CARDINAL HEALTH 107, LLC]

Original source / bibliographic reference

Authors: Cardinal Health 107, LLC

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_25881038] Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!

Original source / bibliographic reference

Authors: Russo M, Rifici C, Sessa E, D'Aleo G, Bramanti P, Calabrò RS.

Year: 2015

Source type: Primary / secondary publication; design and use described in the individual review

DOI: 10.1186/s40199-015-0109-6

PMID: 25881038

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility